The inducible prostaglandin E synthase mPGES-1 regulates growth of endometrial tissues and angiogenesis in a mouse implantation model
Lab / animal
OA: closed
CC0
⤵ 8 in-corpus citations
AI-generated summary
This study investigated the role of the inducible prostaglandin E synthase mPGES-1 in regulating endometrial growth and angiogenesis during mouse implantation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis is one of the most common gynecological diseases in women of reproductive age. Although cyclooxygenase (COX)-2 inhibitors are effective in the treatment of endometriosis, the adverse cardiovascular effects associated with these inhibitors have limited their use. Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme downstream of COX-2 in prostaglandin E(2) biosynthesis. Previously, we developed mPGES-1 knockout mice (mPGES-1(-/-)) and have identified for the first time the roles of ectopic lesion- and host-associated mPGES-1 in angiogenesis and the growth of endometrial tissues. When mPGES-1(-/-) endometrial fragments were implanted into wild type (WT) mice (mPGES-1(-/-)→WT), or WT fragments implanted into mPGES-1(-/-) mice (WT→mPGES-1(-/-)), the growth of the implants was suppressed at days 14 and 28 after implantation, compared toWT→WT transplantation. An even greater degree of suppression was observed in mPGES-1(-/-) endometrial fragments implanted into mPGES-1(-/-) mice (mPGES-1(-/-)→mPGES-1(-/-)). After WT-WT implantation, mPGES-1 expression was localized at the border of the implanted endometrial tissues. Microvessel density, determined by CD31 immunostaining, was markedly suppressed in the mPGES-1(-/-) endometrial fragments implanted into mPGES-1(-/-) mice, with some suppression also observed in the mPGES-1(-/-)→WT and WT→mPGES-1(-/-) groups. The expression of vascular endothelial growth factor (VEGF-A) was significantly reduced in mPGES-1(-/-) endometrial tissues implanted into mPGES-1(-/-) mice at days 14 and 28, in comparison to the WT→WT group. These results suggested that mPGES-1 enhanced angiogenesis and growth of the endometrial implant, and indicate that mPGES-1 may be a good therapeutic target for endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (42)
- Advances in the management of endometriosis: an update for clinicians via openalex
- Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters via openalex
- A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy via openalex
- A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice via openalex
- Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein via openalex
- Endometriosis and angiogenesis via openalex
- Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications via openalex
- Epidemiology of endometriosis via openalex
- Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis via openalex
- Expression of inducible microsomal prostaglandin E synthase in local lesions of endometriosis patients via openalex
- Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases via openalex
- Mechanistic and therapeutic implications of angiogenesis in endometriosis via openalex
- Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis via openalex
- Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis via openalex
- Treatment of endometriosis via openalex
- W2096874183 via openalex
- W2109776354 via openalex
- W2135166720 via openalex
- W2147330842 via openalex
- W2157213771 via openalex
- W2161740453 via openalex
- W2165011857 via openalex
- W2165663767 via openalex
- W2166667647 via openalex
- W2171239203 via openalex
- W2319962899 via openalex
- W2322133447 via openalex
- W6601830869 via openalex
- W1602331691 via openalex
- W1969247204 via openalex
- W2025221853 via openalex
- W2037921925 via openalex
- W2039274017 via openalex
- W2040095832 via openalex
- W2049619918 via openalex
- W2058097591 via openalex
- W2060132531 via openalex
- W2071716296 via openalex
- W2072192090 via openalex
- W2075340577 via openalex
- W2081010076 via openalex
- W2082457469 via openalex
Cited by (8)
- Inhibition of TP signaling promotes endometriosis growth and neovascularization 2023
- Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice 2020
- Inhibition of receptor activity-modifying protein 1 suppresses the development of endometriosis and the formation of blood and lymphatic vessels 2020
- VEGF Receptor 1-Expressing Macrophages Recruited from Bone Marrow Enhances Angiogenesis in Endometrial Tissues 2019
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? 2018
- Basic mechanisms of vascularization in endometriosis and their clinical implications 2018
- Pathological functions of hypoxia in endometriosis 2015
- Female Infertility and Free Radicals: Potential Role in Endometriosis and Adhesions 2012
Source provenance
- europepmc
- last seen: 2026-10-28T06:16:56.634860+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:08:28.697392+00:00
License: CC0
· commercial use OK